Latest news with #JakeLeach
Yahoo
13-05-2025
- Business
- Yahoo
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO
SAN DIEGO, May 13, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating officer, which he has held since 2022. With more than 21 years of leadership experience at Dexcom, Mr. Leach helped steer the company's biosensing platforms since the launch of its first commercial system. In his chief operating officer role, he provides end-to-end responsibility for product development at Dexcom as well as oversight of executive leadership functions, including global operations, research and development, quality management, regulatory and medical affairs. In his role as president, Mr. Leach will take on the additional responsibility of oversight of Dexcom's corporate development and strategy efforts. "My confidence in Dexcom's future opportunities and the quality of our leadership have never been greater," said Kevin Sayer, chairman and chief executive officer. "Jake has strengthened the company's ability to innovate and achieve ambitious goals that will benefit the future of metabolic health. I have no doubt that he will build upon these accomplishments with his promotion to president." "There are few companies in the world with an opportunity to address the greatest challenges in global health while simultaneously benefiting our customers, shareholders and communities," said Mr. Leach. "Taking on the role of president at this moment in our company's history is incredibly exciting and I look forward to working with Kevin to lead Dexcom into a bright future." About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR View source version on Contacts Media Contact James Investor Contact Sean Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
13-05-2025
- Business
- Business Wire
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating officer, which he has held since 2022. With more than 21 years of leadership experience at Dexcom, Mr. Leach helped steer the company's biosensing platforms since the launch of its first commercial system. In his chief operating officer role, he provides end-to-end responsibility for product development at Dexcom as well as oversight of executive leadership functions, including global operations, research and development, quality management, regulatory and medical affairs. In his role as president, Mr. Leach will take on the additional responsibility of oversight of Dexcom's corporate development and strategy efforts. 'My confidence in Dexcom's future opportunities and the quality of our leadership have never been greater,' said Kevin Sayer, chairman and chief executive officer. 'Jake has strengthened the company's ability to innovate and achieve ambitious goals that will benefit the future of metabolic health. I have no doubt that he will build upon these accomplishments with his promotion to president.' 'There are few companies in the world with an opportunity to address the greatest challenges in global health while simultaneously benefiting our customers, shareholders and communities,' said Mr. Leach. 'Taking on the role of president at this moment in our company's history is incredibly exciting and I look forward to working with Kevin to lead Dexcom into a bright future.' About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR
Yahoo
06-05-2025
- Health
- Yahoo
ŌURA rolls out glucose app linked with Dexcom's CGM Stelo
ŌURA has signalled an entry into the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom's over-the-counter (OTC) continuous glucose monitor (CGM) Stelo. The integration between the Oura smart ring and Stelo is the culmination of a partnership between ŌURA and Dexcom in November 2024. The diabetes device giant invested $75m into Finland-based ŌURA to enable data flow between their respective products. The Glucose feature on the Oura app will show daily glucose readings set against periods of meals, sleep, stress, and activity. Data will be extracted from Stelo, the first biosensor approved by the US Food and Drug Administration (FDA) for use without a prescription. Oura will also provide insights to users on how glucose interacts with meals, stress, and daily movement. This, the ring developer says, will help patients learn lifestyle habits that help them maintain or achieve optimal glucose levels. 'Personalised guidance and insights are essential for helping people understand how their lifestyle choices affect their body, while also encouraging them to make informed health decisions that can improve their overall quality of life,' said Jake Leach, executive vice-president and chief operating officer at Dexcom. The glucose feature was launched alongside Meals, an AI-powered tool that provides nutrition information from photographs of food. When launched, Meals and Glucose will be available on iOS and Android for US-based Oura users, with plans to launch Meals internationally later this year. The partnership between ŌURA and Dexcom has signalled a new chapter in the consumer health and medical device sector convergence. ŌURA is fast becoming a household name in the wearable technology sector, thanks to its smart ring. The device measures sleep, stress, and cardiovascular data, among others. It spurred the company to nearly double its annual sales in 2024 to reach around $500m, with 2.5 million rings sold worldwide. Dexcom, meanwhile, is a significant player in the diabetes medical device market, occupying around 74% of the CGM market share in the US, according to analysis by GlobalData. Experts have previously said the partnership between the two companies has the potential to improve adherence and behaviour changes, both critical for long-term diabetes management. One of the key financial aspects of the partnership was that both Dexcom and ŌURA would co-market and cross-sell each other's products. That is indeed now a reality, with new and existing Oura members able to purchase Stelo directly from the smart ring developer for $99. The CGM can be bundled with or without a ring, representing a model example of consumer health and medtech product combination, though this is currently only available in the US.
Yahoo
06-05-2025
- Health
- Yahoo
ŌURA rolls out glucose app linked with Dexcom's CGM Stelo
ŌURA has signalled an entry into the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom's over-the-counter (OTC) continuous glucose monitor (CGM) Stelo. The integration between the Oura smart ring and Stelo is the culmination of a partnership between ŌURA and Dexcom in November 2024. The diabetes device giant invested $75m into Finland-based ŌURA to enable data flow between their respective products. The Glucose feature on the Oura app will show daily glucose readings set against periods of meals, sleep, stress, and activity. Data will be extracted from Stelo, the first biosensor approved by the US Food and Drug Administration (FDA) for use without a prescription. Oura will also provide insights to users on how glucose interacts with meals, stress, and daily movement. This, the ring developer says, will help patients learn lifestyle habits that help them maintain or achieve optimal glucose levels. 'Personalised guidance and insights are essential for helping people understand how their lifestyle choices affect their body, while also encouraging them to make informed health decisions that can improve their overall quality of life,' said Jake Leach, executive vice-president and chief operating officer at Dexcom. The glucose feature was launched alongside Meals, an AI-powered tool that provides nutrition information from photographs of food. When launched, Meals and Glucose will be available on iOS and Android for US-based Oura users, with plans to launch Meals internationally later this year. The partnership between ŌURA and Dexcom has signalled a new chapter in the consumer health and medical device sector convergence. ŌURA is fast becoming a household name in the wearable technology sector, thanks to its smart ring. The device measures sleep, stress, and cardiovascular data, among others. It spurred the company to nearly double its annual sales in 2024 to reach around $500m, with 2.5 million rings sold worldwide. Dexcom, meanwhile, is a significant player in the diabetes medical device market, occupying around 74% of the CGM market share in the US, according to analysis by GlobalData. Experts have previously said the partnership between the two companies has the potential to improve adherence and behaviour changes, both critical for long-term diabetes management. One of the key financial aspects of the partnership was that both Dexcom and ŌURA would co-market and cross-sell each other's products. That is indeed now a reality, with new and existing Oura members able to purchase Stelo directly from the smart ring developer for $99. The CGM can be bundled with or without a ring, representing a model example of consumer health and medtech product combination, though this is currently only available in the US.
Yahoo
10-04-2025
- Health
- Yahoo
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
Dexcom G7 15 Day* is now cleared in the US for people age 18 years and above with diabetes. Now the longest lasting*,†,1 and most accurate1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes. For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system. SAN DIEGO, April 10, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0%,3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range.4-8 "The approval of Dexcom G7 15 Day marks another major innovation for Dexcom," said Jake Leach, executive vice president and chief operating officer at Dexcom. "By listening to the needs of our users, we're proud to offer the longest lasting wearable and most accurate CGM, giving people the knowledge to better control their diabetes with our best-in-class technology. This milestone sets a new standard in CGM and is a testament to our continued leadership in glucose biosensing. We look forward to bringing it to market in the second half of this year, but in the meantime, we encourage our users to upgrade to our current G7 system to gain the benefits of the most connected CGM brand in the world." New with Dexcom G7 15 Day Longest lasting*,†,1 CGM system with 15.5 days of wear.* Best-in-class accuracy1 with an overall MARD of 8.0%.1,3 Easier glucose management with fewer monthly sensors and reduced monthly waste. Dexcom G7 features included with Dexcom G7 15 Day The only waterproof§ CGM available, keeping you more connected. Manage diabetes, hands-free. Connect your sensor directly to your Apple Watch|| so you can leave your iPhone¶ behind and still see your glucose numbers. Automated activity logging,# simplified meal logging and new medication logging# help you better understand how activity, food and medications impact your glucose in real time. 12-hour grace period to replace finished sensors for a more seamless transition between sessions. Innovative and simple mobile app with Dexcom Clarity integration to easily view glucose patterns, trends and statistics via a range of interactive reports.**,†† Ability to remotely share glucose numbers with caregivers and loved ones for added support and peace of mind.‡‡,9 Enhanced and customizable alert settings for improved discretion. "Dexcom G7 15 Day makes managing diabetes even easier with its extended wear and greater accuracy," said Satish Garg, MD, from Barbara David Center for Diabetes at the University of Colorado School of Medicine. "Data recently released during the 18th international Advanced Technologies and Treatments for Diabetes conference in Amsterdam supports that G7 15 Day is the most accurate CGM for adults." Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch. Dexcom G7 15 Day is expected to launch in the US in the second half of 2025. Visit to get started with Dexcom G7 today. To learn more about Dexcom G7 15 Day and for additional information about when it will be available in the US, visit About Dexcom Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR ____________________ * A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days. †Excludes implantable CGM systems. ‡Compared to a prior generation Dexcom CGM System. §The Dexcom G7 Sensor is water-resistant and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. ||Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. ¶Smart device sold separately. To view a list of compatible devices, visit #Automated activity and medication logging available in Dexcom G7 app only. **Healthcare providers can register for Dexcom Clarity at ††An internet connection is required for patients to send their glucose data to Dexcom Clarity via a compatible smart device: Healthcare providers will only be able to view a patient's glucose data if the patient elects to share it with them through Dexcom Clarity. ‡‡Separate Dexcom Follow app and internet connection required. Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions. 1 Dexcom, Data on File, 2025. 2 Dexcom, Data on File, 2023. 3 Garg SK, et al. Diabetes Technol Ther. 2025. doi: 10.1089/dia.2025.0139. Epub ahead of print. 4 Beck RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 8 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 9 Polonsky WH, et al. Diabetes Technol Ther. 2021;23(3):195-202. View source version on Contacts Media Contact Nadia Conardmediarelations@ Investor Contact Sean Sign in to access your portfolio
